Publisher
Springer International Publishing
Reference57 articles.
1. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist Oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55:641–55.
2. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan;391(10117):219–29.
3. McClure GR, Kaplovitch E, Narula S, Bhagirath VC, Anand SS. Rivaroxaban and aspirin in peripheral vascular disease: a review of implementation strategies and management of common clinical scenarios. Curr Cardiol Rep. 2019 Oct;21(10):115.
4. Combining rivaroxaban with aspirin in stable atherosclerotic vascular disease: clinical evidence from the COMPASS study. Br J Cardiol [Internet]. 2020 [cited 2020 Sep 4]; Available from: https://bjcardio.co.uk/2020/03/combining-rivaroxaban-with-aspirin-in-stable-atherosclerotic-vascular-disease-clinical-evidence-from-the-compass-study/
5. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020 May 21;382(21):1994–2004.